

## UNITED STATES OF AMERICA Federal Trade Commission WASHINGTON, D.C. 20580

September 5, 2017

John R. Ingrassia, Esq. Proskauer Rose LLP Counsel For Grifols, S.A. 1001 Pennsylvania Avenue, N.W. Suite 600 South Washington, DC 20004-2533

Re: In the Matter of Grifols, S.A., and Talecris Biotherapeutics Holdings Corp.

Docket No. C-4322

Dear Mr. Ingrassia:

Pursuant to Rule 2.41(f) of the Commission Rules of Practice, the Commission has determined to approve the Application filed by Grifols, S.A., on June 12, 2017, to modify the Contract Manufacturing Agreement ("CMA") incorporated into the Decision and Order in this matter by approving the draft Amendment to the CMA. In according its approval to Grifol's Application, the Commission has relied upon the information submitted by Grifols S.A., and the Commission has assumed that information to be accurate and complete.

By direction of the Commission.

Donald S. Clark Secretary

cc: Joel Grosberg, Esq.
McDermott Will & Emery
Counsel for Kedrion S.p.A.
The McDermott Building
500 North Capitol Street, N.W.
Washington, D.C. 20001